BioSpace News Archive

The demand within the global actinic keratosis treatment market is set to trace an ascending trajectory in the years to follow.

Healthcare laboratory informatics is an information technology-based application employed in various healthcare organizations to optimize and make efficient the laboratory operations.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for an oral virtual presentation at the annual Conference on Retroviruses and Opportunistic Infections, taking place from 6-10 March 2021.

BIOCORP, a French company specialized in the design, development and manufacturing of innovative medical devices, announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively.

Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to certain US investors 61,363 American Depositary Shares, representing 306,815 ordinary shares of 0.1p each in the Company, in connection with the exercise of pre-existing warrants by such investors at an exercise price of $2.0625 per ADS.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the US healthcare investment bank Chardan decision to make Sensorion one of its top picks for 2021, calling the company “2021’s hidden gem in gene therapy”.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close.

Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus vectors and gene therapies for rare and non-rare diseases, announced the completion of its leadership team.

Medtronic plc, the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice.

Phase 3 OlympiA Trial Evaluated LYNPARZA in Germline BRCA -mutated High-Risk HER2-Negative Early-Stage Breast Cancer Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy